At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GPCR STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD
Trading 12-22 09:55:29 EST
63.33
-1.61
-2.49%
High65.77Low61.87Vol151.68K
Open64.91D1 Closing64.94Amplitude6.00%
Mkt Cap4.38BTradable Cap3.10BTotal Shares69.14M
T/O9.62MT/O Rate0.31%Tradable Shares49.03M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Structure Therapeutics Inc. : H.c. Wainwright Raises Target Price to $90 From $60
THOMSON REUTERS  ·  12-19
Structure Therapeutics Inc. : H.c. Wainwright Raises Target Price to $90 From $60
BUZZ-Obesity pill maker Structure gains after Lilly's pill shows promising trial data
Reuters  ·  12-18
BUZZ-Obesity pill maker Structure gains after Lilly's pill shows promising trial data
BRIEF-Structure Therapeutics Starts Phase 1 Study Of Oral Amylin Agonist ACCG‑2671
Reuters  ·  12-17
BRIEF-Structure Therapeutics Starts Phase 1 Study Of Oral Amylin Agonist ACCG‑2671
Structure Therapeutics Launches Phase 1 Trial of Oral Amylin Agonist ACCG-2671 for Obesity
Reuters  ·  12-17
Structure Therapeutics Launches Phase 1 Trial of Oral Amylin Agonist ACCG-2671 for Obesity
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist Accg-2671 for the Treatment of Obesity
THOMSON REUTERS  ·  12-17
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist Accg-2671 for the Treatment of Obesity
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire  ·  12-17
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up
Reuters  ·  12-12
FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up
Press Release: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs
Dow Jones  ·  12-12
Press Release: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs
Structure Therapeutics Inc : Leerink Partners Raises Target Price to $90.00 From $44.00
THOMSON REUTERS  ·  12-11
Structure Therapeutics Inc : Leerink Partners Raises Target Price to $90.00 From $44.00
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
GlobeNewswire  ·  12-11
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up over 6%; Novo Nordisk, Roche up Nearly 4%; Eli Lilly up Slightly
Tiger Newspress  ·  12-10
Weight-Loss Drugmakers' Stocks Jump. Structure Therapeutics up over 6%; Novo Nordisk, Roche up Nearly 4%; Eli Lilly up Slightly
Structure Therapeutics Prices $650 Million Upsized Public Offering
MT Newswires Live  ·  12-10
Structure Therapeutics Prices $650 Million Upsized Public Offering
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
GlobeNewswire  ·  12-10
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
Structure Therapeutics Plans $500 Million Public Offering
MT Newswires Live  ·  12-09
Structure Therapeutics Plans $500 Million Public Offering
Top Midday Gainers
MT Newswires Live  ·  12-09
Top Midday Gainers
BUZZ-U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart
Reuters  ·  12-09
BUZZ-U.S. STOCKS ON THE MOVE-Five Below, Boeing, Instacart
Sector Update: Health Care Stocks Lower in Afternoon Trading
MT Newswires Live  ·  12-09
Sector Update: Health Care Stocks Lower in Afternoon Trading
What's Going On With Structure Therapeutics (GPCR) Stock Today?
Benzinga_recent_news  ·  12-09
What's Going On With Structure Therapeutics (GPCR) Stock Today?
Structure Therapeutics Shares Surge on Positive Phase 2b Results for Obesity Drug Aleniglipron
MT Newswires Live  ·  12-08
Structure Therapeutics Shares Surge on Positive Phase 2b Results for Obesity Drug Aleniglipron
BUZZ-U.S. STOCKS ON THE MOVE-Micron, NextEra Energy, Ocular Therapeutix
Reuters  ·  12-08
BUZZ-U.S. STOCKS ON THE MOVE-Micron, NextEra Energy, Ocular Therapeutix

Introduction

Company Name.
STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.
Issue price:
--